ArticleJournal of inflammation research2025
Multi-Target Synergy Against Acute Lung Injury: Systems Pharmacology Decoding Dahuang-Huangqin Herb Pair's Therapeutic Mechanism.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting inflammation and coagulation: MMP-9 deficiency exacerbates sepsis induced acute lung injury through fibrinogen-driven inflammation.Respiratory research · 2026Article
- A machine learning integrated multi-omics framework for risk prediction and target discovery in insomnia aggravated sepsis induced acute lung injury.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study investigates the therapeutic mechanisms of Methods: We combined bioactive compound screening of DH-HQ with ALI-related transcriptomics to construct dual interaction networks (herb-compound-target and protein-protein interactions). Core pathways were identified via bioinformatic analyses (GO/KEGG/GSEA) and validated through Mendelian randomization (to confirm gene causality), single-cell RNA sequencing (cell-type specificity), molecular docking (binding stability assessment), and in vivo ALI models (pathological/clinical validation). Results: Our analysis identified 207 active DH-HQ components and 93 therapeutic targets associated with ALI. PPI network analysis revealed five key regulatory targets: Conclusion: This study elucidates DH-HQ's multi-target mechanism in mitigating ALI via synergistic bioactive components (emodin and baicalin) and key pathway modulation. Preclinical evidence confirms efficacy through diagnostic hub genes and compound interactions, yet clinical application demands pharmacodynamic refinement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.